TOYO 's Texas Manufacturing Facility Receives Top Quality Rating in Independent Factory Audit by Intertek CEA

TOYO 's Texas Manufacturing Facility Receives Top Quality Rating in Independent Factory Audit by Intertek CEA

TOKYO, Sept. 21, 2026 /PRNewswire/ -- TOYO Co., Ltd. (Nasdaq: TOYO) (OTC: TOYWF) ("TOYO" or the "Company"), a solar manufacturing company, today announced that its module manufacturing facility in Humble, Texas achieved a strong result in a...

LawZero receives a commitment of up to $300M in joint funding from Canada and Germany

LawZero receives a commitment of up to $300M in joint funding from Canada and Germany

MONTRÉAL, Sept. 16, 2026 /PRNewswire/ -- Today, at ALL IN, Canada and Germany announced funding of up to CAD $300 million for LawZero to develop a fundamentally new form of advanced, safe and capable AI. The rapid acceleration of AI brings important...

GomSpace receives order for fast-deployment satellite solution valued at 2.4 MUSD

GomSpace receives order for fast-deployment satellite solution valued at 2.4 MUSD

STOCKHOLM, Sept. 11, 2026 /PRNewswire/ -- GomSpace North America, LLC has received an order from an undisclosed defense customer in the United States with a value of 2.4 MUSD (22.6 MSEK) The agreement covers GomSpace's unique satellite platform kits...

Scage Future Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares Requirements

Scage Future Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares Requirements

NANJING, China, Sept. 3, 2026 /PRNewswire/ -- Scage Future (Nasdaq: SCAG) ("Scage" or the "Company"), a zero-emission solution provider of new energy heavy-duty commercial vehicles and e-fuel solutions, today announced that on August 27, 2026 the...

ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial

ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial

SHANGHAI, Aug. 14, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in the severely ill RSV...

Farmmi Receives NASDAQ Notification Regarding Minimum Bid Requirements

Farmmi Receives NASDAQ Notification Regarding Minimum Bid Requirements

LISHUI, China, Aug. 13, 2026 /PRNewswire/ -- Farmmi, Inc. (NASDAQ: FAMI) ("Farmmi" or the "Company"), today announced that on August 11, 2026, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is...

SU GROUP HOLDINGS LIMITED RECEIVES NASDAQ STAFF DELISTING DETERMINATION AND INTENDS TO REQUEST HEARING

SU GROUP HOLDINGS LIMITED RECEIVES NASDAQ STAFF DELISTING DETERMINATION AND INTENDS TO REQUEST HEARING

Timely hearing request will stay suspension of trading and Form 25 filing pending Nasdaq Hearings Panel decision; approved share consolidation expected on or about August 6, 2026 may enable the Company to regain compliance prior to the hearing HONG...

Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production

Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production

First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing. Demonstrated a unified quality system, strict risk assessment protocols, and compliance with rigorous regulatory requirements from...

Hong Kong Airlines × Ocean Park Panda Friends Livery Aircraft Receives Comprehensive Upgrade

Hong Kong Airlines × Ocean Park Panda Friends Livery Aircraft Receives Comprehensive Upgrade

Themed Cabin Interiors and Limited-Edition Collectibles Make Maiden Flight to Chengdu as Giant Pandas Soar Skyward as Tourism Ambassadors HONG KONG, June 25, 2026 /PRNewswire/ -- Since its debut in mid-March this year, the Panda Friends livery...

Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastati

Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastati

European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 17
  • menu
    menu